Everest Medicines To Develop, Commercialize EDDC’s Small Molecules As Potential COVID-19 Oral Antiviral Treatments
Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), and Singapore’s Experimental Drug Development Centre (“EDDC”) today announced a global licensing agreement under which Everest will obtain exclusive worldwide rights to develop,…
Share
